688235 logo

BeiGene XSSC:688235 Stock Report

Last Price

CN¥161.22

Market Cap

CN¥136.8b

7D

-0.5%

1Y

18.5%

Updated

22 Dec, 2024

Data

Company Financials +

688235 Stock Overview

An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. More details

688235 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

BeiGene, Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for BeiGene
Historical stock prices
Current Share PriceUS$161.22
52 Week HighUS$207.98
52 Week LowUS$98.50
Beta0.60
1 Month Change-3.13%
3 Month Change10.32%
1 Year Change18.54%
3 Year Changen/a
5 Year Changen/a
Change since IPO18.10%

Recent News & Updates

Recent updates

Shareholder Returns

688235CN BiotechsCN Market
7D-0.5%-1.9%-1.2%
1Y18.5%-16.2%11.8%

Return vs Industry: 688235 exceeded the CN Biotechs industry which returned -16.2% over the past year.

Return vs Market: 688235 exceeded the CN Market which returned 11.8% over the past year.

Price Volatility

Is 688235's price volatile compared to industry and market?
688235 volatility
688235 Average Weekly Movement7.3%
Biotechs Industry Average Movement8.8%
Market Average Movement8.7%
10% most volatile stocks in CN Market12.8%
10% least volatile stocks in CN Market5.7%

Stable Share Price: 688235 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 688235's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201010,000John Oylerwww.beigene.com

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company’s clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor.

BeiGene, Ltd. Fundamentals Summary

How do BeiGene's earnings and revenue compare to its market cap?
688235 fundamental statistics
Market capCN¥136.82b
Earnings (TTM)-CN¥5.99b
Revenue (TTM)CN¥23.51b

5.8x

P/S Ratio

-22.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688235 income statement (TTM)
RevenueCN¥23.51b
Cost of RevenueCN¥3.84b
Gross ProfitCN¥19.67b
Other ExpensesCN¥25.66b
Earnings-CN¥5.99b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-56.41
Gross Margin83.67%
Net Profit Margin-25.50%
Debt/Equity Ratio29.6%

How did 688235 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 00:24
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BeiGene, Ltd. is covered by 57 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Michael MengBOCI Research Ltd.
Yonglin YanBOCI Research Ltd.